Skip to content

Industry News

Advent International Completes Purchase of Grupo Farmacéutico SOMAR

25 October 2017

Advent International completed its previously announced purchase of Mexican pharmaceutical company Grupo Farmacéutico SOMAR from Endo International plc for approximately US$124m.

(Press Release) Endo International plc (NASDAQ: ENDP) today announced the completion of the previously announced sale of Grupo Farmacéutico SOMAR to Advent International for a purchase price of approximately $124 million, after giving effect to estimated cash, debt and net working capital purchase price adjustments.

“I would like to thank our SOMAR colleagues for all of their contributions to our Company and wish them continued success with Advent International,” said Paul Campanelli, President and CEO. “With the divestiture of SOMAR complete, we look forward to a continued focus on our core strengths as well as execution against our strategic priorities as a highly focused generics and specialty branded pharmaceutical company.”